$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000145983922000029 Filed on May 10, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$25.59M	$22.44M	$25.23M
YoY Change	15.28%	9.77%	13.96%
Cost Of Revenue	$3.465M	$2.983M	$3.375M
YoY Change	45.89%	35.59%	48.03%
Gross Profit	$22.12M	$19.46M	$21.86M
YoY Change	11.61%	6.65%	9.99%
Gross Profit Margin	86.46%	86.71%	86.62%
Selling, General & Admin	$36.52M	$32.74M	$32.74M
YoY Change	23.24%	21.9%	29.34%
% of Gross Profit	165.11%	168.3%	149.79%
Research & Development	$3.478M	$3.580M	$3.049M
YoY Change	10.45%	21.15%	25.47%
% of Gross Profit	15.72%	18.4%	13.95%
Depreciation & Amortization	$792.0K	$713.0K	$650.0K
YoY Change	58.4%	109.71%	91.18%
% of Gross Profit	3.58%	3.66%	2.97%
Operating Expenses	$40.00M	$36.32M	$35.79M
YoY Change	22.01%	21.82%	29.01%
Operating Profit	-$17.88M	-$16.87M	-$13.93M
YoY Change	37.92%	45.73%	77.01%
Interest Expense	-$486.0K	$561.0K	-$533.0K
YoY Change	-145.21%	-47.27%	-47.23%
% of Operating Profit
Other Income/Expense, Net	-$146.0K	-$54.00K	-$13.00K
YoY Change	-1223.08%	-116.07%	-87.0%
Pretax Income	-$18.51M	-$17.41M	-$14.48M
YoY Change	32.42%	42.24%	61.21%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$18.51M	-$17.41M	-$14.48M
YoY Change	32.42%	42.22%	61.21%
Net Earnings / Revenue	-72.36%	-77.59%	-57.38%
Basic Earnings Per Share	-$0.54	-$0.52
Diluted Earnings Per Share	-$543.7K	-$0.52	-$431.3K
COMMON SHARES
Basic Shares Outstanding	33.91M shares	33.79M shares	33.49M shares
Diluted Shares Outstanding	34.05M shares	33.79M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$114.4M	$130.7M	$147.0M
YoY Change	-35.23%	-29.35%	-25.18%
Cash & Equivalents	$24.32M	$27.33M	$63.42M
Short-Term Investments	$90.10M	$103.4M	$83.56M
Other Short-Term Assets	$2.325M	$3.143M	$3.143M
YoY Change	-4.48%	20.88%	20.88%
Inventory	$16.48M	$14.71M	$11.50M
Prepaid Expenses
Receivables	$15.12M	$12.68M	$14.25M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$148.3M	$161.3M	$175.9M
YoY Change	-25.5%	-22.51%	-19.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.42M	$10.28M	$8.992M
YoY Change	121.42%	41.06%	98.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$385.0K	$395.0K	$400.0K
YoY Change	9.38%	7.92%	6.95%
Total Long-Term Assets	$17.81M	$15.59M	$14.64M
YoY Change	116.62%	103.74%	198.71%
TOTAL ASSETS
Total Short-Term Assets	$148.3M	$161.3M	$175.9M
Total Long-Term Assets	$17.81M	$15.59M	$14.64M
Total Assets	$166.1M	$176.8M	$190.5M
YoY Change	-19.86%	-18.03%	-14.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.141M	$4.998M	$3.198M
YoY Change	31.21%	-3.57%	-2.23%
Accrued Expenses	$9.921M	$9.169M	$12.35M
YoY Change	13.96%	-6.95%	21.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change
Total Short-Term Liabilities	$16.67M	$15.45M	$16.89M
YoY Change	32.07%	12.73%	25.39%
LONG-TERM LIABILITIES
Long-Term Debt	$35.08M	$35.02M	$34.97M
YoY Change	-11.49%	-11.43%	-11.36%
Other Long-Term Liabilities	$3.567M	$45.00K	$57.00K
YoY Change	305.34%	-94.66%	-93.33%
Total Long-Term Liabilities	$38.64M	$35.07M	$35.03M
YoY Change	-4.61%	-13.17%	-13.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.67M	$15.45M	$16.89M
Total Long-Term Liabilities	$38.64M	$35.07M	$35.03M
Total Liabilities	$55.31M	$54.41M	$56.09M
YoY Change	4.1%	0.59%	4.29%
SHAREHOLDERS EQUITY
Retained Earnings		-$313.3M	-$295.8M
YoY Change		30.96%	23.64%
Common Stock		$3.000K	$3.000K
YoY Change		0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$110.8M	$122.4M	$134.4M
YoY Change
Total Liabilities & Shareholders Equity	$166.1M	$176.8M	$190.5M
YoY Change	-19.86%	-18.03%	-14.63%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$18.51M	-$17.41M	-$14.48M
YoY Change	32.42%	42.22%	61.21%
Depreciation, Depletion And Amortization	$792.0K	$713.0K	$650.0K
YoY Change	58.4%	109.71%	91.18%
Cash From Operating Activities	-$14.84M	-$13.51M	-$12.71M
YoY Change	82.1%	44.37%	61.35%
INVESTING ACTIVITIES
Capital Expenditures	-$2.001M	$2.274M	-$1.775M
YoY Change	-9.5%	15.08%	116.46%
Acquisitions
YoY Change
Other Investing Activities	$12.98M	-$20.33M	$17.15M
YoY Change	-30.93%	294.83%	-125.6%
Cash From Investing Activities	$10.98M	-$22.61M	$15.38M
YoY Change	-33.75%	217.44%	-122.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	1.229M	$169.0K	1.015M
YoY Change	-44.56%	-71.88%	-98.61%
NET CHANGE
Cash From Operating Activities	-14.84M	-$13.51M	-12.71M
Cash From Investing Activities	10.98M	-$22.61M	15.38M
Cash From Financing Activities	1.229M	$169.0K	1.015M
Net Change In Cash	-2.635M	-$36.09M	3.679M
YoY Change	-124.77%	122.54%	-238.31%
FREE CASH FLOW
Cash From Operating Activities	-$14.84M	-$13.51M	-$12.71M
Capital Expenditures	-$2.001M	$2.274M	-$1.775M
Free Cash Flow	-$12.84M	-$15.79M	-$10.94M
YoY Change	116.2%	39.27%	54.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38701
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2216351
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	471 El Camino Real
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Santa Clara
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95050
CY2022Q1	dei	City Area Code CityAreaCode	408
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	207-0700
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	SIBN
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33913049	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27329000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63419000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	103402000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	83560000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	258000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	264000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12682000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14246000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	14705000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	11498000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3143000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3143000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	161261000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	175866000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10276000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8992000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4917000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5248000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	395000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	400000	USD
CY2022Q1	us-gaap	Assets Assets	176849000	USD
CY2021Q4	us-gaap	Assets Assets	190506000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4998000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3198000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9169000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12353000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1286000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1339000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15453000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16890000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35024000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34973000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3889000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4166000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	57000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	54411000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	56086000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33872363	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33872363	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33674085	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33674085	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	435590000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	429914000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	104000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	352000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-313259000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-295849000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	122438000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134420000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	176849000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	190506000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22439000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20442000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2983000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2200000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	19456000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	18242000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25605000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20922000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3580000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2955000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7139000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5940000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	36324000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	29817000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16868000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11575000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	73000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	61000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	561000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1064000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-54000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	336000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17410000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-115000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-248000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	21000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17658000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12336000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33792326	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33792326	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32691578	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32691578	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134420000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	169000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5507000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-248000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17410000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	122438000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	169363000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	601000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4030000	USD
CY2021Q1	sibn	Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions	9000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-115000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	21000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	161667000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5507000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4030000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17410000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	713000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	340000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-244000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-331000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	51000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	88000	USD
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-31000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-104000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1603000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-581000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3178000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1725000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-20000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2086000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1059000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3171000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1945000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13512000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9359000	USD
CY2022Q1	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	25000000	USD
CY2021Q1	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	33200000	USD
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	45334000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	38346000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2274000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1976000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22608000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7122000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	169000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	601000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	601000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-139000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-337000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-36090000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16217000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63419000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53581000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27329000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37364000	USD
CY2022Q1	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	0	USD
CY2021Q1	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	9000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	241000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1195000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	The Company and Nature of Business<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The Company introduced its first generation iFuse implant in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company received $63.0 million of net proceeds from its first follow-on public offering of 4,300,000 shares of the Company's common stock, of which 2,490,053 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 645,000 shares of the Company's common stock, at a public offering price of $21.50 per share. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the selling stockholders on a pro-rated basis. Public offering cost of $0.4 million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2 million allocated to selling of shares by the selling stockholders was recognized as transaction costs within general and administrative expenses on the consolidated statements of operations in the year ended December 31, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received $71.6 million of net proceeds from its second follow-on public offering of shares of the Company's common stock, of which 3,000,000 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 478,507 shares of the Company's common stock, at a public offering price of $22.00 per share. In addition to the shares sold by the Company in this second follow-on offering, the selling stockholder sold 190,053 shares of the Company's common stock previously held by the selling stockholder at a price to the public of $22.00 per share. The Company did not receive any proceeds from the sale by the selling stockholder. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to continuing risk and uncertainties as a result of the COVID-19 pandemic, and is closely monitoring the impact of the pandemic on all aspects of its business, including the impacts on its customers, patients that would benefit from procedures involving the Company's products, employees, suppliers, vendors, business partners and distribution channels. Economies worldwide continue to be negatively impacted by the COVID-19 pandemic, in particular with recurrent mutations of the virus, despite advances in vaccines, and the Company anticipates these disruptions will continue. While the Company has not experienced material disruptions to its supply chain to date, certain of its third-party suppliers have faced delays, product shortages and rising costs resulting from disruptions in the global supply chain, primarily related to the instruments. As a result, the Company is continuing to work closely with its manufacturing partners and suppliers, as well as determining alternative sourcing strategies to enable the Company to source key components and maintain appropriate inventory levels to meet customer demand. As such the Company's future results of operations and liquidity could be adversely impacted by a variety of factors related to the COVID-19 pandemic, including those discussed in the section entitled "Risk Factors" in this report. As of the date of issuance of these condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain.</span></div>
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the condensed consolidated financial statements primarily includes the fair value of performance-based restricted stock unit awards. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22439000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20442000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3507000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	852000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2933000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9854000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-239209000	USD
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	21778000	USD
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	21778000	USD
CY2022Q1	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	103686000	USD
CY2022Q1	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	284000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	103402000	USD
CY2022Q1	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	125464000	USD
CY2022Q1	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	284000	USD
CY2022Q1	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	125180000	USD
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	57829000	USD
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	57829000	USD
CY2021Q4	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	83595000	USD
CY2021Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2021Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	39000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	83560000	USD
CY2021Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	141424000	USD
CY2021Q4	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2021Q4	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	39000	USD
CY2021Q4	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	141389000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	300000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13900000	USD
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	800000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17916000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15958000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7640000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6966000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10276000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8992000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	700000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	300000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7250000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10055000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	497000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	995000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1422000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1303000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9169000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12353000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	264000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	263000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	6000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	13000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	258000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	264000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	409000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	282000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	104000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	42000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	513000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	324000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	408000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	285000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	37000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M3D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M23D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0575
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0575
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1213000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1544000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1491000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	990000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	531000	USD
CY2022Q1	sibn	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	10000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5779000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	604000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5175000	USD
CY2022Q1	us-gaap	Purchase Obligation PurchaseObligation	600000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	1200000	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35700000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35700000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	93000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	100000	USD
CY2022Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	583000	USD
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	627000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	35024000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	34973000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35024000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34973000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	7292000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	17500000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10908000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35700000	USD
CY2021Q4	sibn	Social Security Tax Employer Deferral Cares Act SocialSecurityTaxEmployerDeferralCARESAct	500000	USD
CY2022Q1	sibn	Social Security Tax Employer Deferral Cares Act SocialSecurityTaxEmployerDeferralCARESAct	500000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1963360	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2009513	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.73
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	34798	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.85
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	11355	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.46
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.86
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1000000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q4	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	0	shares
CY2022Q1	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	0	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5507000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4030000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33792326	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33792326	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32691578	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32691578	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17410000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4452030	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4379350	shares

Files In Submission

Name	View Source	Status
R3.htm	Edgar Link	pending
0001459839-22-000029-index-headers.html	Edgar Link	pending
0001459839-22-000029-index.html	Edgar Link	pending
0001459839-22-000029.txt	Edgar Link	pending
0001459839-22-000029-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sibn-20220331.htm	Edgar Link	pending
sibn-20220331.xsd	Edgar Link	pending
sibn-20220331_cal.xml	Edgar Link	unprocessable
sibn-20220331_def.xml	Edgar Link	unprocessable
sibn-20220331_htm.xml	Edgar Link	completed
sibn-20220331_lab.xml	Edgar Link	unprocessable
sibn-20220331_pre.xml	Edgar Link	unprocessable
sibn-ex311_331202210xq.htm	Edgar Link	pending
sibn-ex312_331202210xq.htm	Edgar Link	pending
sibn-ex321_331202210xq.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2022 Q2 Form 10-Q Financial Statement

#000145983922000029 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2022 Q2 Form 10-Q Financial Statement

#000145983922000029 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn